APTO - Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents
- Aptose shares are weak in post-ASH trading as the Phase I CG-806 study has yet to produce a clinical response in B-cell malignancies.
- Three B-cell patients did see some tumor reduction at lower doses of CG-806, and the expansion to 750mg (and possibly higher doses) could finally drive meaningful responses.
- A safety signal at 750mg will require an expanded dosing cohort, pushing out the development timeline a bit, but it's unclear if this was a true dose-limiting toxicity event.
- Further data updates should come in 1H'21, but the shares could drift some in the meantime.
For further details see:
Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents